WS #10134
FDA advisory committee unanimously votes 9-0 that benefits of Moderna's mRNA-1010 seasonal flu vaccine outweigh risks for adults 50+.
Moderna Flu Vaccine FDA AdComm
FDA advisory committee unanimously votes 9-0 that benefits of Moderna's mRNA-1010 seasonal flu vaccine outweigh risks for adults 50+.